Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center, Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  osteosarcoma, Ewing sarcoma
Results 1-25 of 447 for your search:
Start Over
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: CABONE, NCI-2014-01927, 9620, NCT02243605
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
MRI in Measuring Biomarkers of Early Treatment Response in Patients With Osteosarcoma or Ewing Sarcoma
Phase: No phase specified
Type: Diagnostic
Age: 13 and over
Trial IDs: VICC SAR 1275, NCI-2013-01359, NCT01882231
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Age: 12 and over
Trial IDs: SARC028, NCI-2015-00320, NCT02301039
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
Effect of Radiation on Bone in Patients with Cancer of the Sacrum
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-208, NCI-2015-00893, NCT02323295
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Phase: No phase specified
Type: Tissue collection/Repository
Age: 21 and under
Trial IDs: AEWS07B1, NCI-2009-00370, CDR0000544202, COG-AEWS07B1, NCT00899990
Physical Therapy in Young Patients With Lower Extremity Malignancies Before Surgery
Phase: No phase specified
Type: Behavioral study
Age: 6 to 30
Trial IDs: PTSARC, NCI-2012-01920, NCT01674101
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Olaparib and Temozolomide in Treating Patients with Recurrent or Metastatic Ewing Sarcoma Previously Treated with Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-115, NCI-2013-01821, NCT01858168
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
Study of Tumor Samples From Patients With Ewing Sarcoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 50 and under
Trial IDs: COG-AEWS08B1, NCI-2009-00372, CDR0000614591, AEWS08B1, NCT00898053
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
Irinotecan Hydrochloride, Temozolomide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Ewing Sarcoma
Phase: Phase II
Type: Treatment
Age: 1 to 40
Trial IDs: 13-068, NCI-2013-01094, NCT01864109
Cyclophosphamide, Topotecan Hydrochloride, and Bevacizumab in Treating Patients With Relapsed or Refractory Ewing Sarcoma or Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: 11-183, NCI-2012-00005, POE10-01, NCT01492673
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Start Over